Related references
Note: Only part of the references are listed.A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2012)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2012)
Circulating tumor cells in prostate cancer: A potential surrogate marker of survival
Jerome Doyen et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Matthew J. Schiewer et al.
CANCER DISCOVERY (2012)
Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
J. Chad Brenner et al.
CANCER CELL (2011)
Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target?
Michael C. Haffner et al.
CLINICAL CANCER RESEARCH (2011)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation
Juan Camilo Barreto-Andrade et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly(ADP-ribose) Polymerase
Xiaofeng Li et al.
DRUG METABOLISM AND DISPOSITION (2011)
Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Christina M. Annunziata et al.
CLINICAL CANCER RESEARCH (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements
Michael C. Haffner et al.
NATURE GENETICS (2010)
ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
Joann P. Palma et al.
CLINICAL CANCER RESEARCH (2009)
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer
Thomas D. Penning et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Howard I. Scher et al.
LANCET ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2008)
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia
Stanley K. Liu et al.
RADIOTHERAPY AND ONCOLOGY (2008)
Recurrent gene fusions in prostate cancer
Chandan Kumar-Sinha et al.
NATURE REVIEWS CANCER (2008)
ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
Cherrie K. Donawho et al.
CLINICAL CANCER RESEARCH (2007)
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
David R. Shaffer et al.
CLINICAL CANCER RESEARCH (2007)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
DP Petrylak et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse
JMN de Murcia et al.
EMBO JOURNAL (2003)
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
V Schreiber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma
M Shiobara et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1
F Dantzer et al.
BIOCHEMISTRY (2000)
A phase II study of temozolomide in hormone-refractory prostate cancer
JP van Brussel et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
The response of Parp knockout mice against DNA damaging agents
M Masutani et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
